A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects
Data Collection
Bacterial Infections and Mycoses+7
+ Bacterial Infections
+ Communicable Diseases
Treatment Study
Summary
Study start date: November 1, 2002
Actual date on which the first participant was enrolled.Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.850 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 8 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Male or female subjects, ≥ 8 years of age and a weight of ≥ 35 kilograms * Subjects with selected culture-positive infections caused by a multiple antibiotic-resistant pathogen presumed to be susceptible to tigecycline * Subjects who have failed or are intolerant of other available appropriate antibiotic therapies or whose pathogens are resistant to other available antibiotics Exclusion Criteria: * Subjects who are moribund with an expected survival of less than 2 weeks. * Subjects who have been designated as "Do Not Resuscitate", unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from potentially curative antibiotic therapy * Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents